<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01309633</url>
  </required_header>
  <id_info>
    <org_study_id>NP01/27/10</org_study_id>
    <nct_id>NCT01309633</nct_id>
  </id_info>
  <brief_title>Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)</brief_title>
  <official_title>Phase II Open-label Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Systemic Therapy for Locally Advanced or Metastatic Nasopharyngeal Carcinoma (NPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      - Hypothesis&#xD;
&#xD;
      We hypothesise that intermittent dosing of the anti-angiogenic RTKI sunitinib or bevacizumab&#xD;
      prior to systemic cisplatin and gemcitabine chemotherapy to transiently &quot;normalise&quot; tumour&#xD;
      vasculature in patients with locally advanced or metastatic NPC will allow greater efficiency&#xD;
      in drug and oxygen delivery, thus potentiating sensitivity to chemotherapy. We hypothesise&#xD;
      that a loading dose of sunitinib for 7 days is required to achieve this sensitization effect&#xD;
      prior to the first cycle of chemotherapy, and that this effect can subsequently be maintained&#xD;
      by a 7 day course of sunitinib prior to each subsequent cycle of chemotherapy. The other&#xD;
      hypothesis tested is that bevacizumab 7 days prior to chemotherapy will achieve normalization&#xD;
      of tumor vasculature as well, and may induce changes in the tumor microenvironment that is&#xD;
      beneficial for antitumour effect.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Primary objectives&#xD;
&#xD;
             1. To determine the pathological CR* rate of intermittent sunitinib or bevacizumab&#xD;
                administered with combination cisplatin and gemcitabine as systemic therapy for&#xD;
                locally advanced or metastatic NPC.&#xD;
&#xD;
             2. To determine the safety and tolerability of intermittent sunitinib or bevacizumab&#xD;
                administered with combination cisplatin and gemcitabine as systemic therapy for&#xD;
                locally advanced or metastatic NPC.&#xD;
&#xD;
        -  Secondary objectives&#xD;
&#xD;
             1. To determine the clinical RR (complete and partial response)+ of intermittent&#xD;
                sunitinib or bevacizumab administered with combination cisplatin and gemcitabine as&#xD;
                systemic therapy for locally advanced or metastatic NPC.&#xD;
&#xD;
             2. To evaluate the pharmacodynamic effects (imaging, circulating and tissue) of&#xD;
                intermittent sunitinib or bevacizumab administered with combination cisplatin and&#xD;
                gemcitabine as systemic therapy for locally advanced or metastatic NPC.&#xD;
&#xD;
             3. To evaluate the early pharmacodynamic effects (imaging, circulating and tissue) of&#xD;
                2 loading doses of sunitinib (ie., 12.5mg or 25mg) and 2 dose level of bevacizumab&#xD;
                (ie. 7.5mg/kg or 2.5mg/kg) given 1 week prior to administration of cisplatin and&#xD;
                gemcitabine chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2, 2011</start_date>
  <completion_date type="Actual">March 11, 2019</completion_date>
  <primary_completion_date type="Actual">March 11, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>2 years</time_frame>
    <description>Rates of clinical response (complete and partial clinical response).&#xD;
Rates of pathological complete responses.&#xD;
Progression-free survival.&#xD;
Haematologic and non-haematologic toxicities, as well as serious adverse events.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1) Arm A&#xD;
Day -6 to Day 0 (total 7 days):&#xD;
Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B&#xD;
Day -6 to Day 0 (total 7 days):&#xD;
Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm C Day -7: IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm D Day -7: IV bevacizumab 2.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12.5mg sunitinib with Cisplatin and Gemcitabine</intervention_name>
    <description>1) Arm A&#xD;
Day -6 to Day 0 (total 7 days):&#xD;
Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Arm A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25mg Sunitinib alternating with Cisplatin and Gemcitabine</intervention_name>
    <description>Arm B&#xD;
Day -6 to Day 0 (total 7 days):&#xD;
Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Arm B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine</intervention_name>
    <description>Day -7: IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered.</description>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>Arm C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine</intervention_name>
    <description>Day -7: IV bevacizumab 2.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered</description>
    <arm_group_label>Arm D</arm_group_label>
    <other_name>Arm D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients may be included in the study only if they meet all of the following criteria:&#xD;
&#xD;
          -  Male or female patients aged 21 years and above.&#xD;
&#xD;
          -  Patients with histologically confirmed WHO Type II or III NPC.&#xD;
&#xD;
          -  Tumour stage III, IVA (T4 N0-2 M0), IVB (Any T N3 M0) or IVC (Any T Any N M1)&#xD;
             according to the American Joint Committee on Cancer (AJCC) 2010 criteria.&#xD;
             Alternatively, patients with locally advanced recurrent or metastatic NPC for which&#xD;
             systemic chemotherapy is indicated will be eligible.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.&#xD;
&#xD;
          -  Adequate organ function including the following:&#xD;
&#xD;
             a. Bone marrow function i. Haemoglobin ≥ 9g/dl ii. Absolute neutrophil count (ANC) ≥&#xD;
             1.5 x 109/L iii. Platelet count ≥ 100 x 109/L.&#xD;
&#xD;
             b. Liver function i. Bilirubin &lt; or = upper limit of normal (ULN) ii. Alkaline&#xD;
             phosphatase (ALP) and gamma-glutamyl transpeptidase (GGT) &lt; or = 2.5x ULN iii. Alanine&#xD;
             transaminase (ALT) and aspartate transaminase (AST) &lt; or = ULN iv. Prothrombin time&#xD;
             (PT) within the normal range for the institution.&#xD;
&#xD;
             c. Renal function i. Plasma creatinine within the normal range for the institution or&#xD;
             calculated creatinine clearance (by the Cockcroft-Gault formula) &gt; 60mL/min.&#xD;
&#xD;
             d. Serum amylase and lipase &lt; or = 1.5x ULN.&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
          -  Recovery from any previous drug- or procedure-related toxicity to National Cancer&#xD;
             Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0 Grade&#xD;
             0 or 1 (except alopecia), or to baseline preceding the prior treatment.&#xD;
&#xD;
          -  Signed informed consent obtained before any study specific procedure. Subjects must be&#xD;
             able to understand and be willing to sign the written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded from the study for any of the following reasons:&#xD;
&#xD;
          -  Previous or concurrent anti-cancer chemotherapy, immunotherapy, radiotherapy or any&#xD;
             other investigational therapy.&#xD;
&#xD;
          -  Patients who cannot swallow or patients with chronic gastrointestinal disease or&#xD;
             conditions that may hamper compliance and/or absorption of the tested product.&#xD;
&#xD;
          -  Any concomitant condition that could compromise the objectives of this study and/or&#xD;
             the patient's compliance (eg. severe medical conditions such as uncontrolled&#xD;
             infection, poorly controlled diabetes mellitus, hypercalcaemia, psychiatric&#xD;
             disorders).&#xD;
&#xD;
          -  Major thoracic and/or abdominal surgery in the preceding 3 weeks.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) seropositivity, hepatitis B or C&#xD;
             seropositivity.&#xD;
&#xD;
          -  In the investigator's opinion, patients with a current or previous history of&#xD;
             clinically significant liver disease within the previous 2 years.&#xD;
&#xD;
          -  History of cardiac disease: congestive heart failure &gt; New York Heart Association&#xD;
             (NYHA) Class II; active coronary artery disease (unstable angina [anginal symptoms at&#xD;
             rest] or new-onset angina [began within the last 3 months] or myocardial infarction&#xD;
             within the past 6 months). Cardiac arrhythmias requiring anti-arrhythmic therapy&#xD;
             (β-blockers or digoxin are permitted).&#xD;
&#xD;
          -  Uncontrolled hypertension (failure of diastolic blood pressure to fall below 90 mmHg,&#xD;
             despite the use of ≥ 3 anti-hypertensive drugs or systolic blood pressure greater than&#xD;
             150 mmHg).&#xD;
&#xD;
          -  Dehydration NCI-CTCAE Grade 2 or higher.&#xD;
&#xD;
          -  Subjects with serious non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
          -  Subjects with arterial or venous thrombotic or embolic events such as cerebrovascular&#xD;
             accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary&#xD;
             embolism within the 6 months before start of study medication.&#xD;
&#xD;
          -  Subjects with renal impairment (creatinine clearance by the Cockcroft-Gault formula) ≤&#xD;
             60mL/min) or on dialysis.&#xD;
&#xD;
          -  Persistent proteinuria of NCI-CTCAE Grade 3 or higher (&gt; 3.5 g/24 hours, measured by&#xD;
             urine protein/creatinine ratio on a random urine sample).&#xD;
&#xD;
          -  Clinically significant bleeding (NCI-CTCAE Grade 3 or higher) within 30 days prior to&#xD;
             start of study medication.&#xD;
&#xD;
          -  Subjects unable to swallow oral medications.&#xD;
&#xD;
          -  Subjects with seizure disorder requiring anticonvulsant medication.&#xD;
&#xD;
          -  History of organ allograft.&#xD;
&#xD;
          -  Subjects with evidence or history of disorders of coagulation or thrombosis.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Women of childbearing potential not employing adequate contraception. Women of&#xD;
             childbearing potential must have a pregnancy test performed a maximum of 7 days before&#xD;
             start of study medication, and a negative result must be documented before start of&#xD;
             study medication. Women of childbearing potential and men, must agree to use adequate&#xD;
             contraception (barrier method of birth control) upon signing the informed consent form&#xD;
             until at least 3 months after the last study drug administration. The definition of&#xD;
             adequate contraception will be based on the judgment of the treating investigator or a&#xD;
             designated associate.&#xD;
&#xD;
          -  Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the subject's participation in the study or evaluation of the study results.&#xD;
&#xD;
          -  Known or suspected allergy to the investigational agent or any agent given in&#xD;
             association with this study.&#xD;
&#xD;
          -  Any condition that is unstable or could jeopardize the safety or compliance of the&#xD;
             subject in the study.&#xD;
&#xD;
          -  Previous or concurrent cancer which is distinct in primary site or histology from the&#xD;
             cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal&#xD;
             cell carcinoma, superficial bladder tumors (Ta, Tis &amp; T1) or any cancer curatively&#xD;
             treated &gt; 3 years prior to study entry.&#xD;
&#xD;
          -  Interstitial lung disease with ongoing signs and symptoms at the time of screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boon Cher Goh, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Kent Ridge</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 3, 2011</study_first_submitted>
  <study_first_submitted_qc>March 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2011</study_first_posted>
  <last_update_submitted>July 19, 2019</last_update_submitted>
  <last_update_submitted_qc>July 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>locally advanced</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

